Ira Goldfine, M.D.

My diabetes research concerns the transmembrane signaling mechanisms for the insulin receptor and related receptors. We are carrying out laboratory and clinical studies to understand the cellular defects in insulin action that exist in insulin resistant subjects. We are focusing on two cellular proteins: PC-1/ENPP1, an inhibitor of the insulin receptor; and HMGA1, a nuclear protein that regulates insulin receptor expression. In addition, we are investigating the effects of exercise training, antioxidants, and new anti-diabetic drugs in insulin-resistant subjects. Another project is the preclinical development of small molecule, insulin receptor activators for eventual use diabetic patients. A final area is the development of small molecule inhibitors of the IGF-1 receptor to treat prostate and other cancers.